Celgene-backed Nurix Therapeutics will use the capital to advance two protein modulation-based immuno-oncology drug candidates toward clinical trials.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Susquehanna International Group co-led a series C round for insurance technology developer InsGeek, whose shareholders already include Legend Holdings and Fosun.

Eli Lilly took part in an $80.3m round that pushed chronic illness drug developer Sigilon Therapeutics' overall funding to nearly $200m.

Strategic partner Lyell Immunopharma led a $45m round for Eureka Therapeutics, which will use the money to advance a pipeline that includes a treatment for liver cancer.

Existing backer ShangPharma reinvested in a series B round for the Pfizer-backed macrocyclic peptide drug developer.

Wayra-backed Quit Genius has secured series A funding as it prepares to add alcohol and drug options to its digital smoking and vaping cessation products.

The antibody therapy developer closed a $100m round co-led by Lilly Asia Ventures that will fund phase 3 clinical studies for its lead drug candidates.

Medison Pharma and Partners Healthcare could be in line for exits after the haematological and musculoskeletal disorder therapy developer filed to raise $86.3m.

The pharmaceutical firm was among the investors in a series G round that valued precision medicine technology provider Tempus at $5bn.